Analyst consensus rating
Black Diamond Therapeutics Analyst Rating: none
Direct answer
Black Diamond Therapeutics's consensus rating is none.
7 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $10.00.
Forecast evidence checked October 18, 2026.
Get free Black Diamond Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $1.72
- Average price target
- $10.00
- High price target
- $14.00
- Low price target
- $8.00
- Low target gap
- +365.1%
- Target upside
- +481.4%
- High target gap
- +714%
- Target range width
- 348.8%
- Consensus rating
- none
- Analysts
- 7
- Evidence date
- October 18, 2026
- Valid through
- October 25, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Black Diamond Therapeutics?
Black Diamond Therapeutics has a verified none consensus. The same dataset has an average price target of $10.00.
How far are Black Diamond Therapeutics's low and high targets from the recorded price?
The low target implies +365.1%, while the high target implies +714%.
How many analysts are included in Black Diamond Therapeutics's consensus?
The verified consensus includes 7 analysts.
How is Black Diamond Therapeutics's target upside or downside calculated?
The average target of $10.00 is divided by the recorded price of $1.72, then one is subtracted to produce +481.4%. This does not guarantee a future return.
When was Black Diamond Therapeutics's analyst forecast verified?
The data was verified on 2026-10-18. The dataset is valid through 2026-10-25.